50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.23 (-2.98%)
GOOGL   98.14 (-0.61%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.23 (-2.98%)
GOOGL   98.14 (-0.61%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.23 (-2.98%)
GOOGL   98.14 (-0.61%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.23 (-2.98%)
GOOGL   98.14 (-0.61%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
NASDAQ:DRIO

DarioHealth - DRIO Stock Forecast, Price & News

$4.09
+0.02 (+0.49%)
(As of 09/26/2022 04:27 PM ET)
Add
Compare
Today's Range
$4.02
$4.24
50-Day Range
$3.74
$7.16
52-Week Range
$3.66
$19.39
Volume
89,385 shs
Average Volume
230,417 shs
Market Capitalization
$93.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.94

DarioHealth MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
217.1% Upside
$12.94 Price Target
Short Interest
Bearish
5.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.50mentions of DarioHealth in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.72) to ($2.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

731st out of 1,069 stocks

Surgical & Medical Instruments Industry

77th out of 104 stocks

DRIO stock logo

About DarioHealth (NASDAQ:DRIO) Stock

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

Receive DRIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DarioHealth and its competitors with MarketBeat's FREE daily newsletter.

DRIO Stock News Headlines

DRIO: Suite Solution
See More Headlines
Receive DRIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DarioHealth and its competitors with MarketBeat's FREE daily newsletter.

DRIO Company Calendar

Last Earnings
8/15/2022
Today
9/26/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRIO
Employees
200
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.94
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$8.75
Forecasted Upside/Downside
+216.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-76,760,000.00
Net Margins
-301.07%
Pretax Margin
-300.94%

Debt

Sales & Book Value

Annual Sales
$20.51 million
Book Value
$5.16 per share

Miscellaneous

Free Float
19,739,000
Market Cap
$93.98 million
Optionable
Not Optionable
Beta
1.27

Key Executives

  • Mr. Erez RaphaelMr. Erez Raphael (Age 49)
    CEO & Director
    Comp: $986.17k
  • Mr. Richard A. Anderson (Age 53)
    Pres & GM of North America
    Comp: $582.67k
  • Mr. Zvi Ben David (Age 61)
    CFO, Treasurer & Sec.
    Comp: $437.61k
  • Mr. Dror BacherMr. Dror Bacher (Age 47)
    Chief Operating Officer
    Comp: $429.21k
  • Dov Oppenheim
    Co-Founder & Production Chief
  • Josh Fischer
    Sr. VP of Operations & Compliance
  • Claudia Levi
    Content & Communications Mang.
  • Mary Mooney
    VP of Marketing
  • Limor Drezner
    VP HR & Chief of Staff
  • Mr. Olivier R. Jarry (Age 61)
    Sr. VP of Strategy & Bus. Devel.













DRIO Stock - Frequently Asked Questions

Should I buy or sell DarioHealth stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DRIO shares.
View DRIO analyst ratings
or view top-rated stocks.

What is DarioHealth's stock price forecast for 2022?

4 analysts have issued 1 year target prices for DarioHealth's shares. Their DRIO share price forecasts range from $8.75 to $15.00. On average, they anticipate the company's share price to reach $12.94 in the next twelve months. This suggests a possible upside of 215.5% from the stock's current price.
View analysts price targets for DRIO
or view top-rated stocks among Wall Street analysts.

How have DRIO shares performed in 2022?

DarioHealth's stock was trading at $12.97 at the beginning of 2022. Since then, DRIO stock has decreased by 68.4% and is now trading at $4.10.
View the best growth stocks for 2022 here
.

When is DarioHealth's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our DRIO earnings forecast
.

How were DarioHealth's earnings last quarter?

DarioHealth Corp. (NASDAQ:DRIO) issued its earnings results on Monday, August, 15th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.03. The firm had revenue of $6.18 million for the quarter, compared to the consensus estimate of $8.27 million. DarioHealth had a negative trailing twelve-month return on equity of 77.24% and a negative net margin of 301.07%. During the same period in the previous year, the business earned ($0.99) EPS.

What other stocks do shareholders of DarioHealth own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include Aeterna Zentaris (AEZS), Vascular Biogenics (VBLT), Nano Dimension (NNDM), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL).

What is DarioHealth's stock symbol?

DarioHealth trades on the NASDAQ under the ticker symbol "DRIO."

Who are DarioHealth's major shareholders?

DarioHealth's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (7.57%), Clal Insurance Enterprises Holdings Ltd (6.80%), Collaborative Holdings Management LP (5.34%), Millennium Management LLC (2.14%), MAI Capital Management (1.52%) and Renaissance Technologies LLC (0.42%). Insiders that own company stock include Adam K Stern, Dennis M Mcgrath, Dror Bacher, Erez Raphael and Oded Cohen.
View institutional ownership trends
.

How do I buy shares of DarioHealth?

Shares of DRIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DarioHealth's stock price today?

One share of DRIO stock can currently be purchased for approximately $4.10.

How much money does DarioHealth make?

DarioHealth (NASDAQ:DRIO) has a market capitalization of $94.21 million and generates $20.51 million in revenue each year. The company earns $-76,760,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis.

How many employees does DarioHealth have?

The company employs 200 workers across the globe.

How can I contact DarioHealth?

DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The official website for the company is www.mydario.com. The company can be reached via phone at (833) 914-3796, via email at ir@mydario.com, or via fax at 972-4770-4059.

This page (NASDAQ:DRIO) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.